Dark

Check out our API

AKBLF
ALK-ABELLO AS B SHS NEW
stock OTC

Inactive

Nov 21, 2022

14.00USD-0.709%(-0.10)500

Pre-market

0.00USD-100.000%(-14.10)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 1, 2021

04:00AM EST ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma PR Newswire

Jun 3, 2021

08:25AM EDT ALK Acquires OTIPRIO From Otonomy, Inc. RTTNews

08:02AM EDT ALK Acquires OTIPRIO(r) (ciprofloxacin otic suspension), Broadening Treatment PR Newswire

Apr 19, 2021

08:01AM EDT Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis PR Newswire

Oct 28, 2020

08:02AM EDT Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies PR Newswire

Share